In this article, we will talk about the 10 most undervalued quality stocks to buy according to analysts.

Janssen's monthly injectable formulation (Invega Sustenna) landed approval back in 2009, which was followed by 3-month ...

One example of this was from Janssen’s PRIDE trial for Invega Sustenna, in which the primary endpoint for this randomised pragmatic trial was not the traditional interviewer administered ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA HAFYERA contains the active ingredient paliperidone palmitate.

Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at least 4 months. Establish tolerability with Invega Sustenna prior to initiating.

J&J's current daily oral formulation, monthly injectable Invega Sustenna product and three-monthly depot Invega Trinza brought in sales of $1.9 billion in the first six months of this year.

New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile ...

The consensus estimate for Erleada sales is $769 million, while our model projects sales to be $755.2 million. Other products ...

This leaflet answers some of the common questions about Invega Trinza. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist.

September 21, 2024, marked the seventh anniversary of the significant amendments to the Patented Medicines (Notice of ...

Paliperidone is a prescription medicine used in the treatment of schizophrenia and mania. It works by modulating the action of certain chemical messengers in the brain that affect thoughts ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...